Metabolic fate of human immunoactive sterols in Mycobacterium tuberculosis
T. Varaksa, S. Bukhdruker, I. Grabovec, E. Marin, A. Kavaleuski, A. Gusach, K. Kovalev, I. Maslov, A. Luginina, D. Zabelskiy, R. Astashkin, M. Shevtsov, S. Smolskaya, A. Kavaleuskaya, P. Shabunya, A. Baranovsky, V. Dolgopalets, Y. Charnou, A. Savachka, R. Litvinovskaya, A. Hurski, E. Shevchenko, A. Rogachev, A. Mishin, V. Gordeliy, , N. Strushkevich
Abstract
Mycobacterium tuberculosis (Mtb) infection is among top ten causes of death worldwide, and the number of drug-resistant strains is increasing. The direct interception of human immune signaling molecules by Mtb remains elusive, limiting drug discovery. Oxysterols and secosteroids regulate both innate and adaptive immune responses. Here we report a functional, structural, and bioinformatics study of Mtb enzymes initiating cholesterol catabolism and demonstrated their interrelation with human immunity. We show that these enzymes metabolize human immune oxysterol messengers. Rv2266, the most potent among them, can also metabolize vitamin D3 (VD3) derivatives. High-resolution structures show common patterns of sterols binding and reveal a site for oxidative attack during catalysis. Finally, we designed a compound that binds and inhibits three studied proteins. The compound shows activity against Mtb H37Rv residing in macrophages. Our findings contribute to molecular understanding of suppression of immunity and suggest that Mtb has its own transformation system resembling the human phase I drug-metabolizing system.Competing Interest StatementA.Gi. and E.S. are employees of MT-Medicals LLC. The other authors declare no competing interests.View Full Text
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mycobacterium tuberculosis inactivates host oxysterols to impair macrophage cholesterol homeostasis
Andrew Roth, Mohsen Ali Asgari, … Jennifer A. Philips·bioRxiv·Oct 5, 2026
- Fragment-based development of small molecule inhibitors targeting Mycobacterium tuberculosis cholesterol metabolism
Madeline E. Kavanagh, Kirsty J. McLean, … Anthony G. Coyne·Journal of Medicinal ChemistryPeer-reviewed·Jul 14, 2025
- Macrophage Cholesterol Homeostasis Underpins the role of Sertraline as an Adjunctive Agent in Tuberculosis Therapy.
Kanika Bisht, Riya Sahu, … Vivek Rao·bioRxiv·Jul 18, 2025
- Inhibition of Mycobacterium tuberculosis DosRST two-component regulatory system signaling by targeting response regulator DNA binding and sensor kinase heme
H. Zheng, B. Aleiwi, … R. B. Abramovitch·bioRxiv·Sep 11, 2018
- Inflammasome activation dictates the efficacy of antimycobacterial activity of frontline TB drugs
Vivek Rao, Anjali Singh, … Ranjan Kumar Nanda·bioRxiv·Apr 2, 2025
- Diverse Ligands for Mycobacterial CYP124 Identified from Plant and Marine Compounds
Leonid A. Kaluzhskiy, Evgeniy O. Yablokov, … Alexis Ivanov·BiochimiePeer-reviewed·Feb 26, 2026